Cephalon's CNS and oncology businesses offset poor pain performance
06 May 2009
Simon Varcoe
Please Login to read the full article.
06 May 2009
Simon Varcoe
simon.varcoe@informa.com
Cephalon's first-quarter total revenues rose by 17% to $520 million despite increased costs and a 3% decline its pain business. Net income increased by 44% to $43.8 million.
The biopharmaceutical company's growth was mainly driven by its central nervous system (CNS) franchise, which grew...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
